Related Experiment Videos

Anti-thrombin action of low-dose acetylsalicylic acid

Biagio Di Micco1, Giovanni Colonna, Pierpaolo Di Micco

  • 1Facoltà di Scienze MM.FF.NN, Università del Sannio, 82100 Benevento, Italy.

European Journal of Pharmacology
|January 22, 2003
PubMed

Insights

Low-dose aspirin therapy for coronary arteries reduces free thrombin by forming thrombin/antithrombin complexes. This occurs through inhibiting platelet factor 4 release, enhancing heparin availability.

Area of Science:

  • Cardiovascular Medicine
  • Pharmacology
  • Hematology

Background:

  • Low-dose aspirin is a standard treatment for coronary artery disease.
  • The precise mechanism of aspirin's action in this context remains incompletely understood.

Purpose of the Study:

  • To elucidate the mechanism by which low-dose aspirin exerts its therapeutic effects in coronary artery patients.
  • To investigate the impact of daily aspirin on thrombin generation and related pathways.

Main Methods:

  • Patients with coronary artery disease received 100 mg/day of aspirin.
  • Assessed thrombin generation and the formation of thrombin/antithrombin (TAT) complexes.
  • Investigated the role of platelet factor 4 and heparin availability.

Main Results:

  • Aspirin treatment did not attenuate overall thrombin generation.
  • Aspirin significantly reduced free thrombin levels by promoting TAT complex formation.
  • Inhibition of platelet factor 4 release from alpha-granules was observed, leading to increased heparin availability.

Conclusions:

  • Low-dose aspirin's efficacy in coronary artery therapy involves reducing free thrombin, not by preventing its generation.
  • The mechanism is linked to enhanced antithrombin activity via suppressed platelet factor 4 release and increased heparin availability.

Related Concept Videos